Key Insights

Highlights

Success Rate

52% trial completion

Published Results

11 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

16.4%

11 terminated out of 67 trials

Success Rate

52.2%

-34.3% vs benchmark

Late-Stage Pipeline

9%

6 trials in Phase 3/4

Results Transparency

92%

11 of 12 completed with results

Key Signals

11 with results52% success11 terminated

Data Visualizations

Phase Distribution

62Total
Not Applicable (16)
Early P 1 (2)
P 1 (21)
P 2 (17)
P 3 (6)

Trial Status

Active Not Recruiting25
Recruiting13
Completed12
Terminated11
Withdrawn5
Unknown1

Trial Success Rate

52.2%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (67)

Showing 20 of 20 trials
NCT04789681Phase 2Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

NCT04267848Phase 3Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT04751747Not ApplicableActive Not Recruiting

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT06498635Phase 3Recruiting

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06632327Phase 3Recruiting

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

NCT02194738Not ApplicableActive Not Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT04092283Phase 3Active Not Recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT05802186Not ApplicableRecruiting

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

NCT04183218Completed

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

NCT05017025Phase 1Active Not Recruiting

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

NCT05096663Phase 2Active Not Recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT04067830Phase 2Recruiting

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT03735095Phase 1Completed

Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer

NCT06732401Phase 3Active Not Recruiting

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT04430725Active Not Recruiting

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

NCT04902040Phase 1Terminated

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT04073745Phase 1Active Not Recruiting

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT04701307Phase 2Active Not Recruiting

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

NCT03948100Not ApplicableRecruiting

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

Scroll to load more

Research Network

Activity Timeline